文献速递临床试验与 GCP基础与转化研究

精氨酸治疗镰状细胞病急性疼痛发作:STArT随机临床试验

Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

STArT 3期双盲随机试验纳入3至21岁镰状细胞病急性疼痛发作患者,比较静脉精氨酸与安慰剂。因无效提前终止:精氨酸组与安慰剂组危象缓解中位时间相近(60.8小时 vs 65.8小时),总胃肠外阿片用量、疼痛评分、患者报告结局及安全性事件均无显著差异。

要点

  • 静脉精氨酸未缩短镰状细胞病急性疼痛发作的危象缓解时间
  • 精氨酸组与安慰剂组总胃肠外阿片用量、疼痛评分及安全性事件无显著差异
  • 该3期试验因无效提前终止,不支持精氨酸常规用于此类急性疼痛发作

核心结论

  • 在镰状细胞病急性疼痛发作的儿童和年轻成人中,静脉精氨酸治疗未缩短危象缓解时间,也不优于安慰剂。

研究设计与样本

  • 前瞻性3期双盲随机临床试验,2021年6月21日至2024年6月13日在美国10家儿童医院开展。
  • 纳入3至21岁因镰状细胞病急性疼痛发作至急诊并需胃肠外阿片类药物的患者,随机接受静脉精氨酸(200 mg/kg后每8小时100 mg/kg直至出院,n=129)或生理盐水安慰剂(n=142)。

主要发现

  • 274例随机参与者中271例接受研究药物,平均年龄14.3岁(SD 4.3岁),51%为男性,92%为黑人。
  • 精氨酸组与安慰剂组危象缓解中位时间分别为60.8小时(IQR 34.8-109.0小时)与65.8小时(IQR 31.1-111.1小时),绝对差异7.2小时(95% CI -21.6至35.9小时)。
  • 总胃肠外阿片用量、疼痛评分、患者报告结局及安全性事件均未见显著差异。

关键数值与推荐

  • 主要结局危象缓解定义为从首次研究药物给药至末次静脉阿片类药物剂量的小时数。
  • 试验因无效提前终止。

临床怎么用

  • 对于镰状细胞病急性疼痛发作的儿童和年轻成人,现有证据不支持使用静脉精氨酸来缩短危象缓解时间或减少阿片用量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute pain episodes are the leading cause of emergency department visits and hospitalizations for patients with sickle cell disease (SCD), yet US Food and Drug Administration-approved drugs for acute pain episodes are lacking. During acute pain episodes, patients develop acute arginine deficiency associated with longer time to crisis resolution and greater total parenteral opioid use. Multiple single-center, phase 2 randomized clinical trials have shown that arginine is safe, is opioid sparing, improves cardiopulmonary function, and reduces length of hospital stay. OBJECTIVE: To determine the efficacy and safety of intravenous arginine for SCD acute pain episodes. DESIGN, SETTING, AND PARTICIPANTS: Prospective, phase 3, double-blind randomized clinical trial conducted between June 21, 2021, and June 13, 2024, in 10 US children's hospitals enrolling patients aged 3 to 21 years presenting to the emergency department with SCD acute pain episodes requiring parenteral opioids. INTERVENTIONS: Patients were randomized to receive intravenous arginine (200 mg/kg followed by 100 mg/kg every 8 hours until discharge; n = 129) or saline placebo (n = 142). MAIN OUTCOMES AND MEASURES: The primary outcome was time to crisis resolution, defined as hours from initial study drug delivery to last intravenous opioid dose. Secondary outcomes included total parenteral opioid use (intravenous morphine equivalents in milligrams per kilogram from first study drug dose to last intravenous opioid dose), pain scores, and patient-reported outcomes. RESULTS: Of 274 randomized participants, 271 received study drug; the mean age was 14.3 years (SD, 4.3 years), 51% were male, and 92% were Black. The trial was halted early for futility, as time to crisis resolution was similar in those receiving arginine vs placebo (median, 60.8 hours [IQR, 34.8-109.0 hours] vs 65.8 hours [IQR, 31.1-111.1 hours], respectively; absolute difference, 7.2 hours; 95% CI, -21.6 to 35.9 hours). No significant differences were seen in total parenteral opioid use, pain scores, patient-reported outcomes, or safety events. CONCLUSIONS AND RELEVANCE: Arginine therapy did not shorten time to crisis resolution compared with placebo among children and young adults with SCD acute pain episodes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04839354.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Morris CR, Hatabah D, Korman R, et al. Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial. JAMA. 2026. PMID: 42616542. doi:10.1001/jama.2026.13310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。